Impinj (PI): A RECORD Quarter Built on a Once-a-Year Cheque — Is PI Stock a Buy?

Impinj, Inc. (PI) Q2 2026 — Reported after the close on July 29 (quarter ended June 30, 2026). Revenue $108.4M (+11% YoY) vs a $103-106M guide; non-GAAP EPS $0.86 vs ~$0.80 (GAAP $0.39); adjusted EBITDA $30.7M; non-GAAP gross margin 60.9% — all records. The stock closed +5.9% at $147.49 on July 30, then $151.36 on July 31. The record is partly a calendar artifact: ~$17.0M of the $108.4M is the annual NXP patent licence, which the 10-Q says is recognised IN THE SECOND QUARTER OF EACH YEAR at essentially no cost. THE CALL: AVOID (4/5, GREAT COMPANY, IMPOSSIBLE PRICE) — base-case value ~$89.0 vs ~$151.36 today. KEY METRICS: - CALL: AVOID 4/5 — fair value ~$89 vs $151.36 (-41%). Base DCF $83 at 10.5%; bear $32, bull $158; prob-weighted 25/50/25 = $89. STREET: Buy, honest consensus ~$180 (+19%). Published targets are stale — aggregators quote $190-$241, many set last October at $240. Dated and named post-print: Jefferies RAISED to $190, Needham CUT to $168, both Buy; UBS Neutral, Evercore In Line. We DIFFER. - THE $17M THAT MADE THE RECORD: the annual NXP licence is booked entirely in Q2 each year at ~100% margin — 16% of revenue and 7.3 of the 60.9 gross-margin points. CFO Cary Baker: 'excluding licensing revenue, second quarter product gross margin was 53.6%' (vs 52.6%) and 'adjusted EBITDA margin was 15%' (vs the 28.3% headline). Product revenue was $91.4M, not $108.4M. - NXP CAN CANCEL IT: the 10-Q says NXP pays annually until the Indicator Patents expire 'in about 2034' or 'until NXP earlier terminates', and may terminate 'on any April 1' once it designs out all valid claims. The fee escalates yearly. That $17M is ~55% of the record $30.7M adjusted EBITDA — a third of FY26 cash earnings, sitting in a competitor's option. - EPS GUIDED DOWN 30% ON FLAT REVENUE: Q3 revenue $105.5-108.5M but non-GAAP EPS $0.59-0.63 vs $0.86 and adjusted EBITDA $20.7-22.2M vs $30.7M. The cheque does not repeat and opex rises. In fairness, Baker framed Q3 against '$91.4 million product revenue... a 17% quarter-over-quarter increase at the midpoint' — the product business is genuinely accelerating. - THE YEAR STARTED NOWHERE: Q1 2025 revenue $74.28M; Q1 2026 $74.25M — identical, with a $15.2M GAAP operating loss. The celebrated +46% sequential jump is measured off that. H1 2026 is a GAAP net loss of $13.0M and operating loss of $4.7M. FY2026E ~$388M, about +7% on 2025's $361.1M. - FREE CASH FLOW IS FUNDED BY STOCK: SBC was $31.0M in H1 (~$62M annualised, 16% of revenue) vs ~$55M of 2026E free cash flow; 2025 was $45.9M FCF vs $55.3M SBC. Basic shares went 29.0M to 30.5M (+5.1%) in a year. From GAAP operating income, owner earnings are ~$0. Also: three unnamed customers are 61% of revenue; net cash is only ~+$16M after $247.3M of converts. - REVERSE DCF: at $151.36 (EV ~$4.6B, 11.9x 2026E sales), at 10.5% with 3% terminal growth and a 22% terminal owner-earnings margin, the price needs ~25% revenue growth a year for TEN YEARS — to ~$3.5B. Impinj has compounded at 19% over six years and will do ~7% this year. GENUINELY GOOD: record bookings a 2nd straight quarter, record units, an empty channel into an H2 restock, R&D at 27% of revenue, ~200bps of M800 margin to come. What to watch: Bullish: a clean Q1 2027 (the test the CFO set himself), product revenue over $110M, a disclosed solutions revenue line. Bearish: a third straight Q1 miss, or any sign NXP is terminating the licence. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.